Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Lakefront Biotherapeutics 10/11 29,480 EUR
-1,27% 		-1,27%
vlag Lakefront Biotherapeutics 10/11 33,410 USD
-0,33% 		-0,33%
vlag Larimar Therapeutics Inc 9/11 2,530 USD
+5,86% 		+5,86%
vlag Lexicon Pharmaceuticals Inc 10/11 1,860 USD
+2,20% 		+2,20%
vlag Ligand Pharmaceuticals, Inc. 10/11 314,160 USD
0,00% 		0,00%
vlag Lineage Cell Therapeutics Inc 9/11 1,080 USD
+5,88% 		+5,88%

Nieuws over “Biotechnologie”

10/11 · Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London · Persbericht

10/11 · Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London · Persbericht

10/11 · Lakefront presenteert op de 2026 Jefferies Global Healthcare Conference in Londen · Persbericht

10/11 · Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform · Persbericht

10/11 · Rigel to Present at the Jefferies Global Healthcare Conference in London · Persbericht

10/11 · Co-Diagnostics Reports Third Quarter 2026 Financial Results · Persbericht

10/11 · Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit · Persbericht

10/11 · Disclosure of the Total Number of Voting Rights and Shares Forming the Share Capital · Persbericht

10/11 · Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ® · Persbericht

9/11 · Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS) · Persbericht

9/11 · Cellectis to Report Third Quarter Financial Results on November 12, 2026 · Persbericht

9/11 · Nanobiotix to Participate in Investor Conferences in November · Persbericht

9/11 · NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM · Persbericht

9/11 · Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab · Persbericht

9/11 · What's Next for Anavex Life Sciences Corp. Shareholders After 6.35% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline · Persbericht

9/11 · Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update · Persbericht

9/11 · Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated · Persbericht

9/11 · AXON SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AXON · Persbericht

9/11 · Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology · Persbericht

9/11 · Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026 · Persbericht

9/11 · Compugen Reports Third Quarter 2026 Results · Persbericht

Mijn selecties